The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
To enable company to be future-ready by tapping potential in CDMO space
Open, scalable, end-to-end solution to improve diagnostic quality and efficiency
Time to combine innovation, access and technology to deliver positive patient outcomes
Smart-performance, fully biodegradable biopolymer sourced from renewable raw materials
Nearly 5000 executives and more than 350 exhibitors turned out at the largest post-pandemic pharma packaging event
The company has announced net revenue of Rs. 639.8 crore for Q3 FY23 as compared to Rs. 562.08 crore in the corresponding period of the previous year
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
Subscribe To Our Newsletter & Stay Updated